Skip to main content

Table 1 Clinical and biological characteristics of 52 pediatric posterior fossa (PF) ependymomas

From: Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma

Variables

n = 52 (%)

Age (years)

 

 range

0.9–20.4

 median

3.1

Gender

 

 female

24 (46.2)

 male

28 (53.8)

Extent of resection

 

 GTR

34 (65.4)

 non-GTR

17 (32.7)

 n.a

1 (1.9)

Adjuvant therapy

 

 no

9 (17.3)

 RTX

14 (26.9)

 CTX

5 (9.6)

 RTX and CTX

24 (46.1)

WHO grade

 

 grade II

18 (34.6)

 grade III

34 (65.4)

TNC

 

 positive

46 (88.5)

 negative

6 (11.5)

LAMA2

 

 positive

28 (53.8)

 negative

24 (46.2)

Chromosome 1q

 

 gain

10 (19.2)

 no gain

34 (65.4)

 n.a.

8 (15.4)